Home›Stocks›AIM

AIM — structural market context

AIM ImmunoTech Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 14. Each line shows the earlier value, the later value and their dates.

Price

Close $0.16 (Oct 14) vs $0.17 (Oct 13): −4.77%.

Volume

0.42× its 20-session average (1.3M) on Oct 14.

Includes pre- and post-market trading.

Short interest

Short interest 1.4M shares (settlement Sep 30) vs 2.8M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 1–Sep 14, published Sep 30): 6 days with fails, largest 2.7M shares on Sep 1.

Previous file (settlements Aug 17–Aug 31, published Sep 16): 2 days with fails, largest 15K shares on Aug 19.

No new publication in this window.

Insider filings (Form 4)

None recorded in this window.

AIM short interest & days to cover

SHARES SHORT
1.4M
% OF FLOAT
—
DAYS TO COVER
1.0
CHANGE VS PRIOR
-49.1%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (15d ago)

AIM fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-09 · 36d1K$0.23
2026-09-08 · 37d56K$0.23
2026-09-04 · 41d1.3M$0.23

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

AIM insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 4 purchases · 0 sales

InsiderTypeSharesValueFiled
Equels Thomas K · director, officer: CEO & PresidentBuy (P)24K$5K2026-09-18
Equels Thomas K · director, officer: CEO & PresidentBuy (P)11K$2K2026-09-17
Equels Thomas K · director, officer: CEO & PresidentBuy (P)22K$5K2026-09-16
Equels Thomas K · director, officer: CEO & PresidentBuy (P)6K$1K2026-09-15

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

Frequently asked questions

Are insiders buying AIM?
In the last 12 months of SEC Form 4 filings, AIM recorded 4 insider purchases and 0 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
Is this page telling me to buy or sell AIM?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with A

ACLLY · ACCELLERON INDS LTD ADR - UnspAMIGY · Admiral Group plc, Cardiff UnsAPA · APA CorporationAU · AngloGold Ashanti plcAVHNF · Ackermans & Van Haaren Sa OrdiAAPL · Apple Inc.All A →

This is the teaser.

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.